FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Third quarter in brief
- The company's application related to one of the patent families in the SILC project was granted patent in the US
- Preclinical data for a SILC substance was published in the scientific journal Cancer Immunology Research
- The process to divest the company's research facility at Ideon in Lund has been initiated, for further comments related to the company's liquidity situation see the section "Outlook, including significant risks and uncertainties"
Events after the end of the period
- In October, Active Biotech's partner Teva Pharmaceutical Industries Ltd presented new data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS-ACTRIMS congress
- The Board of directors has decided to initiate negotiations with the trade unions related to the winding up of the companies animal test facility
Financial summary
| SEK M | July-Sept. | Jan.-Sept. | Full-year | |||||
| 2017 | 2016 | 2017 | 2016 | 2016 | ||||
| Net sales | 5.1 | 4.1 | 14.8 | 12.0 | 19.0 | |||
| Operating loss | -6.5 | -11.1 | -44.2 | -41.6 | -55.1 | |||
| Loss for the period | -8.4 | -12.4 | -48.6 | -44.8 | -59.6 | |||
| Loss per share, before and after dilution (SEK) | -0.09 | -0.14 | -0.50 | -0.50 | -0.65 | |||
| Cash and cash equivalents (at the end of the period) | 35.6 | 39.9 | 77.7 | |||||
For further information, please contact:
| Helén Tuvesson, CEO Tel: +46 (0)46-19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c672597f-f52b-4eae-b48b-e96242c94f90
